CRS Stock Recent News

WATERTOWN, Mass., June 02, 2025 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing long-acting, anti-inflammatory sinonasal implants for the treatment of chronic rhinosinusitis (CRS), today announced positive results from the ENLIGHTEN 2 Phase 3 clinical trial of LYR-210 in adult patients with CRS. The ENLIGHTEN 2 trial met its primary endpoint, with LYR-210 demonstrating statistically significant improvement compared to sham control in a composite of the three cardinal symptoms (3CS) of CRS (nasal obstruction, nasal discharge, facial pain/pressure) at week 24 (-1.13; p=0.0078) in patients without nasal polyps.

Here is how Carpenter Technology (CRS) and Aris Mining Corporation (ARMN) have performed compared to their sector so far this year.

Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are ODD, CRS, HRTG, APH, MRX.

– Phase 3 results from ENLIGHTEN 2 pivotal Phase 3 trial of LYR 210 in Chronic Rhinosinusitis (CRS) expected in Q2 2025 – – Phase 3 results from ENLIGHTEN 2 pivotal Phase 3 trial of LYR 210 in Chronic Rhinosinusitis (CRS) expected in Q2 2025 –

Carpenter makes specialized metals used in a multitude of industries, including aerospace, health care and transportation.

CRS, FSFG and BCH made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on May 1, 2025.

Finding strong, market-beating stocks with a positive earnings outlook becomes easier with the Zacks Rank.

FIX, RITM, CCEP, CRS and CNC have been added to the Zacks Rank #1 (Strong Buy) List on May 1, 2025.

Does Carpenter Technology (CRS) have what it takes to be a top stock pick for momentum investors? Let's find out.

Carpenter (CRS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).